No CAD (n=37) | CAD (n=54) | P value | No obstructive CAD (n=82) | Obstructive CAD (n=9) | P value | |||||
---|---|---|---|---|---|---|---|---|---|---|
Demographics | ||||||||||
Age | 45 | ±12 | 53 | ±9 | 0.002 | 50 | ±11 | 56 | ±7 | 0.028 |
Gender, male | 18 | 48.6% | 38 | 70.4% | 0.036 | 51 | 62.2% | 5 | 55.6% | 0.698 |
Disease duration and disease activity | ||||||||||
Disease duration (years) | 7.8 | ±7.6 | 10.8 | ±9.9 | 0.109 | 8.7 | ±8.6 | 17.9 | ±11.3 | 0.015 |
DAPSA(0–64) | 20 | (14, 23) | 19 | (10, 32) | 0.608 | 13 | (9,21) | 6 | (3,24) | 0.972 |
Achieve MDA | 6 | 16.2% | 10 | 18.5% | 0.777 | 13 | 15.9% | 3 | 33.3% | 0.191 |
Traditional CV risk score | ||||||||||
Framingham risk score, % | 6.3 | ±5.6 | 13.3 | ±9.7 | <0.001 | 9.7 | ±8.5 | 17.8 | ±9.8 | 0.009 |
Framingham 10 year CV risk | ||||||||||
Low | 27 | 73.0% | 26 | 48.1% | 0.038 | 51 | 62.2% | 2 | 22.2% | 0.055 |
Intermediate | 8 | 21.6% | 17 | 31.5% | 21 | 25.6% | 4 | 44.4% | ||
High | 2 | 5.4% | 11 | 20.4% | 10 | 12.2% | 3 | 33.3% | ||
Modified Framingham risk score, % | 9.5 | ±8.4 | 20 | ±14.5 | <0.001 | 14.5 | ±12.7 | 26.6 | ±14.6 | 0.009 |
Modified Framingham 10 year CV risk | ||||||||||
Low | 24 | 64.9% | 15 | 27.8% | <0.001 | 37 | 45.1% | 2 | 22.2% | 0.082 |
Intermediate | 9 | 24.3% | 16 | 29.6% | 23 | 28.0% | 2 | 22.2% | ||
High | 4 | 10.8% | 23 | 42.6% | 22 | 26.8% | 5 | 55.6% | ||
Current medication | ||||||||||
Anti-hypertensive drug | 6 | 16.2% | 21 | 38.9% | 0.021 | 21 | 25.6% | 6 | 66.7% | 0.037 |
Diabetic drug | 2 | 5.4% | 8 | 14.8% | 0.188 | 7 | 8.5% | 3 | 33.3% | 0.076 |
NSAIDs | 19 | 51.4% | 30 | 55.6% | 0.693 | 44 | 53.7% | 5 | 55.6% | 0.303 |
csDMARDs | 20 | 54.1% | 34 | 63.0% | 0.395 | 48 | 58.5% | 6 | 66.7% | 0.281 |
bDMARDs | 5 | 13.5% | 15 | 27.8% | 0.017 | 15 | 18.3% | 5 | 55.6% | 0.002 |
Bold values indicate p <0.05.
bDMARDs, biologic DMARDs; csDMARDs, conventional synthetic disease-modifying antirheumatic drugs; DAPSA, disease activity in psoriatic arthritis; MDA, minimal disease activity; NSAIDs, non-steroidal anti-inflammatory drugs.